

Open research – why is it important?

Kevin Ashley Director, Digital Curation Centre www.dcc.ac.uk @kevingashley Kevin.ashley@ed.ac.uk

With thanks to many DCC colleagues for reuse of images

DMPonline, DCC, and the associated logos are registered trademarks of the University of Edinburgh





DCC because good research needs good data



My home – the DCC

- Consultancy
- Training
- Research
- Services
- Guidance
- Events



...and an organisational member of RDA, Datacite, Digital Preservation Coalition & COAR



Why does open research matter?

- Moral and financial reasons:
 - Reusable data improves integrity, speed and cost of research
 - True even if reuse is only by the original creators
 - Working openly open publications, data, workflows, software:
 - Increase speed of research
 - Reduces cost
 - Reduces needless duplication
 - Improves integrity



Open research benefits

Research quality

 How close can we get to the truth?

Research speed

 How quickly can we get to the truth?

Research finance


 How much does the truth cost? Improving one or more of these is of interest to all actors:

- Researchers as data creators
- Researchers as data reusers
- Research institutions
- Funders hence government and society



New research with old data

A network meta-analysis offers a wider picture than a single traditional meta-analysis




Synthesis allows new analyses

Research that cannot be done with any one of these datasets



Data reuse from Hubble







http://www.jisc.ac.uk/whatwedo/programmes/di_directions/strategic UPC training w directions/badc.aspx



Mandates by funders

- DCC has been conducting funder policy analysis for over 12 years
- For the last 5 years, we've been working with SPARC Europe to monitor national data policy in Europe



Findings

- 'Policies' have many forms roadmaps, laws, concordats, Codes, funder policies
- In 2019 11 EU member states have national policy relating to research data
 - ERA: 2 have policy, 1 (Iceland) has active plans
- 9 more have known plans or intentions
- Primarily driven by research funders



Changes over time

2017 2019

11 EC national policies

14 EC national policies

2 ERA policies

4 ERA policies

9 more countries with activity or declared intentions

14 more countries with activity or declared intentions

1 EC member state with no national policy & no known plan to have one.



Open research for selfish reasons

 Sparc Europe/DCC briefing on value of open data to institutions: https://sparceurope.org/newbriefing-paper-value-open-dat

a-research-institutions/



- Self-interest such as citation advantage
 - ☐ Alter, Pienta, Lyle 240%, social sciences *
 - □Piwowar, Vision 9% (microarray data)†
 - ☐ Henneken, Accomazzi 20% (astronomy) #

Edwin Henneken, Alberto Accomazzi, (2011) Linking to Data - Effect on Citation Rates in Astronomy. http://arxiv.org/abs/1111.3618

^{*} Amy Pienta, George Alter, Jared Lyle, (2010) The Enduring Value of Social Science Research: The Use and Reuse of Primary Research Data. http://hdl.handle.net/2027.42/78307

[†] Piwowar H, Vision TJ. (2013) Data reuse & the open data citation advantage. PeerJ PrePrints 1:e1v1 http://dx.doi.org/10.7287/peerj.preprints.1v1



The alternative...

Not being open often has negative consequences.

The case for open data: the Duke clinical trials

9 May, 2011 | in Blogs By: Kevin Ashley

comment, provides a highly readable summary of a long and complex case of flawed clinical research and the difficulties encountered by those trying to expose the flaws. It also provides a strong argument for being open with data and code at an early stage, even where sensitive data is involved.

Since this research involved cancer chemotherapy, the lives of people and their quality of life whilst undergoing treatment potentially depended on the truth of the research findings. As the article shows, falsifying the findings would have been far easier and quicker had the original data, and the methods used to analyse it, been made available from the outset. Expensive clinical trials could have been avoided. Potentially, better treatments could have been brought to trial more quickly once the false promise of this particular intervention was clear.

It's often felt that whilst some subjects may be prime candidates for openness with data, those involving human subjects, and in particular clinical medicine, present too many ethical and regulatory challenges. Examples such as this show that such a position is wrong. Even if ethical and regulatory barriers exist, wider ethical issues the avoidance of unnecessary human suffering being one - demand that we be as open as possible with clinical data. In this case, no identifying information needed to be released to allow others to validate or invalidate this work. Even when the inclusion of identifying information is inescapable, data can still be open in the sense that its existence is public and it is made available to anyone who can satisfy the

Most Read

Site Comments

- Re-skilling for Research observations on an RLUK report
- Re-engineering Libraries for the Data Decade
- New book: Managing Research Data
- 'What's New' Issue 42: February 2012
- How can we evaluate data repositories? Pointers from DryadUK

Incremental project













your family and friends again.

A chemotherapeutic treatment that exacts less of a physical toll would benefit a great many

A chemotherapeutic treatment that exacts less of a physical toll would benefit a great many people. In 2006, a group of researchers at Duke University announced in a research article a major breakthrough that promised precisely that. This was followed by several articles in the same vein; all were published in leading journals and had citation counts that any academic would envy. One paper, in the New England Journal of Medicine, was cited 290 times.



(1 item remaining)



Everything

Breaking news: lawsuit filed against **Duke** for **fraudulent** cancer study

Images

www.naturalnews.com/033561 cancer study fraud.html

Maps

13 Sep 2011 - The plaintiffs claim Duke researchers were engaged in fraudulent and negligent behavior when they set up a clinical trial using cancer patients ...

Videos

How a New Hope in Cancer Fell Apart - NYTimes.com

News

www.nytimes.com/2011/07/08/health/research/08genes.html

Shopping

7 Jul 2011 - But the research at Duke turned out to be wrong. Its gene-based tests proved worthless, and the research behind them was discredited.

More

Journalist Reports Duke Cancer Research Fraud-Duke Reacts ...

www.advocateyourself.org/?p=433

13 Mar 2011 - Journalist Reports Duke Cancer Research Fraud & Duke Hires Her to Ensure Silence. Medical research is at the heart of why health care is ...

Sherburn in Elmet, UK

Breaking news: lawsuit filed against **Duke** for **fraudulent** cancer

Change location

drleonardcoldwell.com/.../breaking-news-lawsuit-filed-against-duke-f...

Pages from the UK

The web

13 Sep 2011 - The plaintiffs claim Duke researchers were engaged in fraudulent and negligent behavior when they set up a clinical trial using cancer patients ...

All results

Fraudulent Cancer Treatment Pushed by Major University

Related searches

www.gaia-health.com/.../000488-cancer-treatment-fraud-university.s...

More search tools

8 Jul 2011 - Cancer & Corruption words with Duke University logo ... This fraud finally resulted in Duke stopping the pseudo-research and the patient trials.

Duke Sued Over Cancer Trials - ABC News

abcnews.go.com/blogs/health/2011/.../duke-sued-over-cancer-trials/

9 Sep 2011 - The trials, which began in 2007 and 2008, were based on work by Dr. Anil

Potti — a former Duke cancer researcher who claimed to have ...

Done

Internet







Some elements of working openly

- Make the EXISTENCE of data, software, workflows etc known – even if the content is not open
- Use permanent identifiers (PIDs) for everything
- Document your plans
 - In clinical research register your trials
- Use the work of others and credit them
- Use recognised standards for metadata & data
- Deposit data with trusted repositories